Mirvetuximab soravtansine in folate receptor alpha-positive, platinum-resistant ovarian cancers: a profile of its use

Funding The preparation of this review was not supported by any external funding.

Authorship and conflict of interest S. Fung and Y. Y. Syed are salaried employees of Adis International Ltd/Springer Nature and declare no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability Not applicable.

Additional information about this Adis Drug Review can be found here.

Abstract  

Mirvetuximab soravtansine (Elahere^TM), an antibody-drug conjugate carrying a maytansinoid payload targeting folate receptor alpha (FRα), is a valuable new treatment option for patients with FRα-positive, platinum-resistant ovarian cancer. Mirvetuximab soravtansine significantly improved objective response rates compared with historical rates in patients with FRα-positive, platinum-resistant ovarian cancer in the phase 2 SORAYA trial. In the confirmatory phase 3 MIRASOL trial, mirvetuximab soravtansine significantly improved median progression-free survival, objective response rates, and median overall survival compared with investigator’s choice of nonplatinum chemotherapy in patients with this indication. Mirvetuximab soravtansine has manageable tolerability, with eye disorders being the most common treatment-related adverse event. 

© Springer Nature Switzerland AG 2024